ClinicalTrials.gg
RecruitingNCT07567625Updated Jul 16, 2026

Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)

An interventional study of Guideline-recommended standard medical therapy alone and DES implantation plus guideline-recommended standard medical therapy in Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI) and Non-ST-Segment Elevation Myocardial Infarction(NSTEMI), sponsored by Harbin Medical University. Recruiting at 48 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Harbin Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 40 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.

Planned enrollment
18th of 97
2,000 · median 320
Started
2026
with 11 others
No phase
51 of 146
21 open now
Primary completion
2029-04
later than 37 of 42 live
Registered
139th of 146
by date
Lead sponsor
7 of 146
Harbin Medical University

Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 18th largest by planned enrollment of the 97 interventional ones that give a count, is one of 12 that started in 2026, is one of 51 with no phase, reaches primary completion later than 37 of the 42 other live ones, and was the 139th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

40 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in ST Elevation Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, open-label, non-inferiority, randomized controlled trial. A total of 2,000 patients with STEMI (\<24 hours or 7-14 days) or NSTEMI will be recruited from at least 20 centers in China. Eligible patients must have residual DS \< 70% at the culprit lesion assessed by QCA, with optional thrombus aspiration, and TIMI flow of grade 3. Patients will be randomly assigned in a 1:1 ratio to the experimental group or the control group. The planned enrollment period is 36 months, and all patients will be followed up for at least 12 months after randomization, with continued follow-up until the end of the study. The primary outcome is the first occurrence of TLF after randomization, defined as the composite of cardiovascular death, target vessel myocardial infarction, ischemia-driven target lesion revascularization. The study aims to verify whether guideline-recommended standard medical therapy is non-inferior to DES implantation combined with guideline-recommended standard medical therapy in AMI patients with non-severe coronary artery stenosis.

A total of 120 participants (60 in the experimental group and 60 in the control group) enrolled at the Second Affiliated Hospital of Harbin Medical University were included in the functional substudy. Using Abbott Pressure Wire™X pressure wire test functional indicators, and explore the incidence of coronary microvascular dysfunction (CMD) as assessed by the index of microcirculatory resistance (IMR) in two groups, and its impact on the rate of the composite endpoint of all-cause death and heart failure readmission occurring for the first time within 12 months.

03

Conditions studied

  • Acute Myocardial Infarction (AMI)
  • ST-Segment Elevation Myocardial Infarction(STEMI)
  • Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)

Keywords

  • AMI
  • DES
  • TLF
  • IMR
  • OCT
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged ≥18 years and ≤75 years;
  2. Diagnosis of type 1 AMI, including STEMI (onset \<24 hours or 7-14 days) or NSTEMI;
  3. After coronary angiography (CAG) ± thrombus aspiration, TIMI flow in the culprit vessel is restored to grade 3 and maintained for at least 5 minutes, with diameter stenosis (DS) \<70% at the culprit lesion (QCA);
  4. Reference diameter of the culprit lesion >2.5 mm and ≤4.0 mm;
  5. Patients or a legally authorized representative must provide written prior to any study related procedure.

Exclusion criteria

Exclusion Criteria:

1.Clinical exclusion criteria:

  1. Severe cardiac dysfunction (Killip/ class ≥ 3) or \< 30%;
  2. Cardiopulmonary resuscitation (CPR) performed at the onset of AMI;
  3. Persistent hemodynamic or cardiac electrical instability after TIMI flow restoration;
  4. to antithrombotic drugs, or concurrent hemorrhagic diseases such as peptic ulcer or coagulation disorders;
  5. Contraindication to contrast;
  6. Severe renal dysfunction [defined as ≤30 ml/min/1.73m² or Scr ≥2.0 mg/dL] without regular dialysis (patients with chronic renal insufficiency on regular dialysis may be considered for enrollment);
  7. Active liver disease, defined as known infectious, neoplastic, or metabolic liver lesions, with and AST >3× (ULN);
  8. Previous history of CABG or PCI for the culprit lesion;
  9. Patients with other concurrent severe diseases and an expected of \<1 year;
  10. Pregnant or lactating women. Women of must use effective measures during the study treatment period;
  11. Inability to comply with the study protocol or other conditions deemed unsuitable for study participation by the investigator.

2.Imaging exclusion criteria:

  1. Non-culprit lesion with DS ≥70% or planned revascularization;
  2. Left main coronary artery lesion with DS ≥50%;
  3. Culprit lesion is a true bifurcation lesion requiring a two-stent strategy;
  4. Long lesion (planned stent length >60 mm);
  5. Culprit lesion with dissection, false lumen, or other conditions necessitating stent implantation;
  6. Target lesion has undergone pre-treatment (such as balloon dilation, rotational atherectomy, etc.).

3.Functional sub study:

  1. Individuals who are allergic to adenosine triphosphate (ATP) or any component in its preparations;
  2. Second and third degree atrioventricular block, sick sinus syndrome (without artificial pacemaker protectors);
  3. Patients with bronchial asthma.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Guideline-recommended standard medical therapy alone

    Dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction.

    Drug: Guideline-recommended standard medical therapy alone

  • Active comparator
    DES implantation plus guideline-recommended standard medical therapy

    DES implantation plus dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction.

    Procedure: DES implantation plus guideline-recommended standard medical therapy

Interventions

  • DrugGuideline-recommended standard medical therapy alone

    Dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction

  • ProcedureDES implantation plus guideline-recommended standard medical therapy

    DES implantation plus dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction.

06

What researchers measure

Primary outcomes

  1. Target Lesion Failure(TLF)

    TLF is defined as a composite endpoint consisting of cardiovascular death, target vessel myocardial infarction and ischemia-driven target lesion revascularization.

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

Secondary outcomes

  1. All-cause death

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  2. Cardiovascular death

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  3. Myocardial infarction (MI)

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  4. Target vessel myocardial infarction

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  5. Coronary Revascularization

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  6. Target vessel revascularization

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  7. Target lesion revascularization

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  8. Ischemia-driven target lesion revascularization

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  9. Stroke

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  10. Rehospitalization for unstable angina pectoris

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  11. Rehospitalization for heart failure

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  12. Major adverse cardiovascular and cerebrovascular events (MACCE)

    MACCE: defined as a composite endpoint consisting of all-cause death, myocardial infarction, stroke, and repeat revascularization.

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  13. Seattle Angina Questionnaire(SAQ)score

    Time frame: From 24 hours after surgery to discharge and the 12th month after discharge

Other outcomes

  1. Definite or probable in-stent thrombosis

    Safety endpoint

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  2. Contrast-induced acute kidney injury(CI-AKI)

    Safety endpoint

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  3. Procedure-related myocardial infarction

    Safety endpoint

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  4. Bleeding Academic Research Consortium(BARC)type 3 and type 5 bleeding

    Safety endpoint

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  5. Microcirculation resistance index(IMR)to assess the incidence of coronary microvascular dysfunction (CMD)

    Exploratory endpoint:Functional sub research

    Time frame: From randomization to the end of the study, median follow-up duration is 30 months.

  6. The first occurrence of all-cause death and readmission due to heart failure within 12 months.

    Exploratory endpoint:Functional sub research

    Time frame: From randomization to the 12th month.

07

Study locations

1 of 48 sites recruiting
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150086, China
    Recruiting
  • Beijing Luhe Hospital Affiliated to Capital Medical University
    Beijing, China
    Not yet recruiting
    • Guangyao Zhai · Contact
  • Fuwai Hospital, Chinese Academy of Medical Sciences
    Beijing, China
    Not yet recruiting
    • Lei Song · Contact
  • Cangzhou Central Hospital
    Cangzhou, China
    Not yet recruiting
    • Jun Zhang · Contact
  • Chengde Medical College Affiliated Hospital
    Chengde, China
    Not yet recruiting
    • Ying Zhang · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, China
    Not yet recruiting
    • Wenjie Tian · Contact
  • The Central Hospital Affiliated to Dalian University of Technology
    Dalian, China
    Not yet recruiting
    • Xiaoqun Zheng · Contact
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, China
    Not yet recruiting
    • Bo Zhang · Contact
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, China
    Not yet recruiting
    • Xin Zhao · Contact
  • Daqing Oilfield General Hospital
    Daqing, China
    Not yet recruiting
    • Zhiqi Sun · Contact
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, China
    Not yet recruiting
    • Wei Yang · Contact
  • The Third Xiangya Hospital of Central South University
    Hunan, China
    Not yet recruiting
    • Yu Cao · Contact
  • Central Hospital of Jiamusi City
    Jiamusi, China
    Not yet recruiting
    • Zhiyuan Weng · Contact
  • The First Affiliated Hospital of Jiamusi University
    Jiamusi, China
    Not yet recruiting
    • Guangyuan Yang · Contact
  • China-Japan Union Hospital of Jilin University
    Jilin City, China
    Not yet recruiting
    • Yuquan He · Contact
  • Jilin Central Hospital
    Jilin City, China
    Not yet recruiting
    • Yijun Shang · Contact
  • The First Hospital of Jilin University
    Jilin City, China
    Not yet recruiting
    • Qian Tong · Contact
  • Shandong Provincial Hospital
    Jinan, China
    Not yet recruiting
    • Haitao Yuan · Contact
  • The Affiliated Hospital of Jining Medical University
    Jining, China
    Not yet recruiting
    • Lijun Gan · Contact
  • Lanzhou University First Hospital
    Lanzhou, China
    Not yet recruiting
    • Ming Bai · Contact
  • Linyi People's Hospital
    Linyi, China
    Not yet recruiting
    • Yanjin Wei · Contact
  • Mudanjiang Cardiovascular Hospital
    Mudanjiang, China
    Not yet recruiting
    • Kai Liu · Contact
  • The First Affiliated Hospital of Nanyang Medical College
    Nanyang, China
    Not yet recruiting
    • Ou Zhang · Contact
  • The Affiliated Hospital of Qingdao University
    Qingdao, China
    Not yet recruiting
    • Zhexun Lian · Contact
  • Qiqihar First Hospital
    Qiqihar, China
    Not yet recruiting
    • Jinhui Zhang · Contact
  • The Second Affiliated Hospital of Qiqihar Medical University
    Qiqihar, China
    Not yet recruiting
    • Xiaojie Wu · Contact
  • The Third Affiliated Hospital of Qiqihar Medical University
    Qiqihar, China
    Not yet recruiting
    • Haifeng Shao · Contact
  • Liaoning Provincial People's Hospital
    Shenyang, China
    Not yet recruiting
    • Bo Luan · Contact
  • Shengjing Hospital of China Medical University
    Shenyang, China
    Not yet recruiting
    • Zhijun Sun · Contact
  • The Fourth Affiliated Hospital of China Medical University
    Shenyang, China
    Not yet recruiting
    • Yuanzhe Jin · Contact
  • The Second Hospital of Hebei Medical University
    Shijia Zhuang, China
    Not yet recruiting
    • Xinshun Gu · Contact
  • Hebei Provincial People's Hospital
    Shijiazhuang, China
    Not yet recruiting
    • Yi Dang · Contact
  • Suihua First Hospital
    Suihua, China
    Not yet recruiting
    • Qiuye Yang · Contact
  • General Hospital of Taiyuan Iron and Steel (Group) Co.
    Taiyuan, China
    Not yet recruiting
    • Huifeng Wang · Contact
  • Shanxi Provincial Cardiovascular Hospital
    Taiyuan, China
    Not yet recruiting
    • Zhulin Zhang · Contact
  • General Hospital of Tianjin Medical University
    Tianjin, China
    Not yet recruiting
    • Qing Yang · Contact
  • TEDA International Cardiovascular Hospital
    Tianjin, China
    Not yet recruiting
    • Wenhua Lin · Contact
  • Tianjin Chest Hospital
    Tianjin, China
    Not yet recruiting
    • Chunjie Li · Contact
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, China
    Not yet recruiting
    • Xueqiang Guan · Contact
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
    Not yet recruiting
    • Xiang Cheng · Contact
  • Wuhan Asia Heart Hospital
    Wuhan, China
    Not yet recruiting
    • Hua Yan · Contact
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, China
    Not yet recruiting
    • Zuyi Yuan · Contact
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Xinjiang, China
    Not yet recruiting
    • Yining Yang · Contact
  • The First Affiliated Hospital of Xinjiang Medical University
    Xinjiang, China
    Not yet recruiting
    • Xiang Ma · Contact
  • Yantai Yuhuangding Hospital
    Yantai, China
    Not yet recruiting
    • Faxin Ren · Contact
  • Fuwai Huazhong Cardiovascular Hospital
    Zhengzhou, China
    Not yet recruiting
    • Chuanyu Gao · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
    Not yet recruiting
    • Jinying Zhang · Contact
  • Zunyi Medical University Affiliated Hospital
    Zunyi, China
    Not yet recruiting
    • Ranzun Zhao · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2029, 33 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 33 months is below that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 5, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Apr 2029
CompletionEst.
Dec 2030
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07567625
Lead sponsor
Harbin Medical University
Responsible party
Yu Bo (Director, cardiology department, the second Affiliated Hospital of Harbin Medical University, Harbin Medical University) — Principal investigator
First posted
May 5, 2026
Start date
Jul 13, 2026
Primary completion
Apr 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jul 16, 2026

Study contacts

Jingbo Hou, Ph.D.
Contact
jingbohou@163.com
13303609625
Bo Yu, Ph.D.
Contact
yubodr@163.com
Bo Yu, Ph.D.
principal investigator · The Second Affiliated Hospital of Harbin Medical University
Jingbo Hou, Ph.D.
principal investigator · The Second Affiliated Hospital of Harbin Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion